Header and Body 3

Technology

Microdevices: 

  • Made with polydimethylsiloxane (PDMS) micromolding, 3D printing or stereolithography using FDA-approved biodegradable polylactic-co-glycolic acid (PLGA) for low cost mass production
  • Adjustable wall thicknesses for the microparticles with ratios of the manufacturing polymers adjusted to control the timing of pulsatile drug releases
  • The hollow core of the microdevice is filled with a drug using an ink jet piezoelectric nozzle and then tightly sealed with an aligned polymeric cap to prevent leakage
  • Devices allow stable encapsulation of different types of nucleic acid and small molecule STING-agonists, or alternatively, other biologic or chemical agents for sustained release delivery

Administration of multiple doses in single injection:

  • Mixed populations of two or more microdevices made with different polymeric compositions are injected at a local tissue site (optimized for drug release kinetics from days to months later)
  • Devices are delivered using standard 23 gauge needles and remain localized at injection sites
  • Single injection STING-agonist delivery triggers local and systemic antitumor immune responses and inhibits tumor growth as effectively as multiple doses of soluble STING agonist
  • Platform can be used for delivery of oncology, vaccine, pain and other classes of therapeutics